These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Drugs against superbugs: private lessons from bacteriophages. Brown ED Trends Biotechnol; 2004 Sep; 22(9):434-6. PubMed ID: 15331220 [TBL] [Abstract][Full Text] [Related]
5. Reinventing phage therapy: are the parts greater than the sum? Fischetti VA; Nelson D; Schuch R Nat Biotechnol; 2006 Dec; 24(12):1508-11. PubMed ID: 17160051 [TBL] [Abstract][Full Text] [Related]
6. Antibacterial application of engineered bacteriophage nanomedicines: antibody-targeted, chloramphenicol prodrug loaded bacteriophages for inhibiting the growth of Staphylococcus aureus bacteria. Vaks L; Benhar I Methods Mol Biol; 2011; 726():187-206. PubMed ID: 21424451 [TBL] [Abstract][Full Text] [Related]
7. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. Becker SC; Foster-Frey J; Donovan DM FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148 [TBL] [Abstract][Full Text] [Related]
8. Phage therapy: a reappraisal of bacteriophages as antibiotics. Inal JM Arch Immunol Ther Exp (Warsz); 2003; 51(4):237-44. PubMed ID: 12956433 [TBL] [Abstract][Full Text] [Related]
10. [Inactivation of staphylococcal and colon bacillus bacteriophage by dendrochin]. Bilaĭ VI; Kharchenko SN Mikrobiol Zh; 1970; 32(5):606-10. PubMed ID: 4252939 [No Abstract] [Full Text] [Related]
11. Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives. Borysowski J; Lobocka M; Międzybrodzki R; Weber-Dabrowska B; Górski A BioDrugs; 2011 Dec; 25(6):347-55. PubMed ID: 22050337 [TBL] [Abstract][Full Text] [Related]
12. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Kutateladze M; Adamia R Trends Biotechnol; 2010 Dec; 28(12):591-5. PubMed ID: 20810181 [TBL] [Abstract][Full Text] [Related]
13. Biotypes, antibiogram and phage types of Staphylococcus epidermis of human origin. Natesan V; Mohapatra LN; Bhujwala RA Indian J Pathol Microbiol; 1980 Jul; 23(3):199-204. PubMed ID: 6450732 [No Abstract] [Full Text] [Related]
14. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. Briones E; Colino CI; Lanao JM J Control Release; 2008 Feb; 125(3):210-27. PubMed ID: 18077047 [TBL] [Abstract][Full Text] [Related]
16. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Staphylococcus aureus are located on beta-hemolysin-converting bacteriophages. van Wamel WJ; Rooijakkers SH; Ruyken M; van Kessel KP; van Strijp JA J Bacteriol; 2006 Feb; 188(4):1310-5. PubMed ID: 16452413 [TBL] [Abstract][Full Text] [Related]
18. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Hanlon GW Int J Antimicrob Agents; 2007 Aug; 30(2):118-28. PubMed ID: 17566713 [TBL] [Abstract][Full Text] [Related]
20. [On the interrelation of the resistance of pathogenic staphylococci to antibiotics, their virulence and phage type]. CHISTOVICH GN Antibiotiki; 1963 Jan; 8():64-7. PubMed ID: 14020901 [No Abstract] [Full Text] [Related] [Next] [New Search]